GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS)
CNY 11.84
(-0.34%)
CNY 11.84
(-0.34%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 861.16 Million CNY | 39.43% |
| 2022 | 637.81 Million CNY | 27.83% |
| 2021 | 498.93 Million CNY | 59.28% |
| 2020 | 313.25 Million CNY | -27.19% |
| 2019 | 430.24 Million CNY | 15.32% |
| 2018 | 373.09 Million CNY | 10.89% |
| 2017 | 336.45 Million CNY | 27.09% |
| 2016 | 264.72 Million CNY | 53.49% |
| 2015 | 172.47 Million CNY | 29.9% |
| 2014 | 132.77 Million CNY | 69.81% |
| 2013 | 78.19 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 275.6 Million CNY | 10.34% |
| 2024 Q1 | 215.63 Million CNY | -42.04% |
| 2024 Q2 | 253.74 Million CNY | 17.67% |
| 2023 Q3 | 191.7 Million CNY | 22.69% |
| 2023 Q4 | 372 Million CNY | 94.05% |
| 2023 FY | 889.3 Million CNY | 39.43% |
| 2023 Q1 | 191.14 Million CNY | -21.14% |
| 2023 Q2 | 156.24 Million CNY | -18.26% |
| 2022 Q2 | 142.73 Million CNY | 50.81% |
| 2022 Q1 | 94.64 Million CNY | -46.54% |
| 2022 FY | 637.81 Million CNY | 27.83% |
| 2022 Q4 | 242.38 Million CNY | 53.36% |
| 2022 Q3 | 158.05 Million CNY | 10.73% |
| 2021 Q4 | 177.03 Million CNY | 39.69% |
| 2021 FY | 498.93 Million CNY | 59.28% |
| 2021 Q2 | 122.02 Million CNY | 66.81% |
| 2021 Q1 | 73.15 Million CNY | -42.91% |
| 2021 Q3 | 126.73 Million CNY | 3.86% |
| 2020 Q4 | 128.13 Million CNY | 146.09% |
| 2020 FY | 313.25 Million CNY | -27.19% |
| 2020 Q2 | 66.86 Million CNY | 1.02% |
| 2020 Q1 | 66.18 Million CNY | -57.73% |
| 2020 Q3 | 52.06 Million CNY | -22.13% |
| 2019 Q1 | 70.19 Million CNY | 0.0% |
| 2019 FY | 430.24 Million CNY | 15.32% |
| 2019 Q4 | 156.56 Million CNY | 49.56% |
| 2019 Q3 | 104.68 Million CNY | 5.96% |
| 2019 Q2 | 98.8 Million CNY | 40.76% |
| 2018 FY | 373.09 Million CNY | 10.89% |
| 2018 Q2 | 89.12 Million CNY | 121.79% |
| 2018 Q1 | 40.18 Million CNY | -58.52% |
| 2017 FY | 336.45 Million CNY | 27.09% |
| 2017 Q1 | 43.74 Million CNY | -46.01% |
| 2017 Q3 | 96.88 Million CNY | 0.0% |
| 2017 Q4 | 96.88 Million CNY | 0.0% |
| 2016 Q4 | 81.01 Million CNY | 0.0% |
| 2016 Q1 | 42.69 Million CNY | -17.14% |
| 2016 Q2 | 42.69 Million CNY | -0.0% |
| 2016 Q3 | 81.01 Million CNY | 89.76% |
| 2016 FY | 264.72 Million CNY | 53.49% |
| 2015 Q3 | 51.52 Million CNY | 71.04% |
| 2015 Q1 | 30.12 Million CNY | -18.62% |
| 2015 Q4 | 51.52 Million CNY | 0.0% |
| 2015 Q2 | 30.12 Million CNY | -0.0% |
| 2015 FY | 172.47 Million CNY | 29.9% |
| 2014 Q3 | 37.01 Million CNY | 28.46% |
| 2014 Q1 | 28.81 Million CNY | 0.0% |
| 2014 FY | 132.77 Million CNY | 69.81% |
| 2014 Q2 | 28.81 Million CNY | 0.0% |
| 2014 Q4 | 37.01 Million CNY | 0.0% |
| 2013 FY | 78.19 Million CNY | 0.0% |